Nuvation Bio Inc.

NUVB

US67080N1019

Biotechnology & Medical Research

Real-time Estimate Cboe BZX Other stock markets 13:25:34 2024-06-04 EDT			5-day change	1st Jan Change
2.625 ^USD	-3.49%		-11.49%	+73.51%

06-01	Nuvation Bio Inc. Announces Data from Pivotal Phase 2 Trust-I Study of its Investigational ROS1 Inhibitor, Taletrectinib, Publishes in Journal of Clinical Oncology and Reports at 2024 ASCO Annual Meeting	CI
05-14	Nuvation Bio Q1 Loss Narrows; Shares Fall After Hours	MT

Panacea Acquisition Corp. has Changed its Name to Nuvation Bio Inc

February 09, 2021 at 12:00 am

On February 09, 2021, Panacea Acquisition Corp. changed its name to Nuvation Bio Inc.

Latest news about Nuvation Bio Inc.

Nuvation Bio Inc. Announces Data from Pivotal Phase 2 Trust-I Study of its Investigational ROS1 Inhibitor, Taletrectinib, Publishes in Journal of Clinical Oncology and Reports at 2024 ASCO Annual Meeting	06-01	CI
Nuvation Bio Q1 Loss Narrows; Shares Fall After Hours	05-14	MT
Nuvation Bio Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024	05-14	CI
RBC Raises Price Target on Nuvation Bio to $5 From $4, Keeps Outperform, Speculative Risk	04-17	MT
Nuvation Bio Closes Acquisition of AnHeart Therapeutics	04-10	MT
Nuvation Bio Inc. Announces Appointment of Directors	04-10	CI
Nuvation Bio Inc. completed the acquisition of AnHeart Therapeutics Ltd	04-08	CI
HC Wainwright Adjusts Nuvation Bio's Price Target to $8 From $5, Maintains Buy Rating	03-28	MT
Nuvation Bio Inc. Appoints Colleen Sjogren as Chief Commercial Officer	03-28	CI
North American Morning Briefing : Stocks Set for -2-	03-28	DJ
Nuvation Bio Shares Jump After Jefferies Upgrade	03-27	MT
Top Premarket Gainers	03-27	MT
Jefferies Upgrades Nuvation Bio to Buy From Hold, Adjusts Price Target to $10 From $1.40	03-27	MT
North American Morning Briefing : Stocks Edge -2-	03-27	DJ
BTIG Upgrades Nuvation Bio to Buy From Neutral, Price Target is $5	03-26	MT
Nuvation Bio Agrees to Acquire AnHeart Therapeutics in All-Stock Deal -- Shares Fall	03-25	MT
Nuvation Bio Inc. entered into an Agreement and Plan of Merger to acquire AnHeart Therapeutics Ltd.	03-24	CI
Nuvation Bio Doses First Patient in Phase 1/2 Study of Advanced Solid Tumor Treatment	03-14	MT
Nuvation Bio Inc. Doses First Patient in Phase 1/2 Study of NUV-1511 for the Treatment of Advanced Solid Tumors	03-14	CI
H.C. Wainwright Raises Price Target on Nuvation Bio to $5 From $4.50, Maintains Buy Rating	03-07	MT
Nuvation Bio Inc. Reports Earnings Results for the Full Year Ended December 31, 2023	02-29	CI
Nuvation Bio Inc. Reports Earnings Results for the Fourth Quarter Ended December 31, 2023	02-29	CI
Nuvation Bio Receives US FDA Clearance for Investigational New Drug Application for NUV-1511	01-08	MT
Nuvation Bio Gets New Drug Application Clearance From FDA for Solid Tumor Treatment	01-08	DJ
Nuvation Bio Inc. Announces Appointment of Robert Mashal to Its Board of Directors	01-08	CI

Nuvation Bio Inc. is a biopharmaceutical company. The Company is engaged in tackling the unmet needs in oncology by developing differentiated and therapeutic candidates. The Company is advancing multiple clinical-stage candidates, including a ROS1 inhibitor, a mutant isocitrate dehydrogenase 1 (mIDH1) inhibitor, a bromodomain and extra-terminal (BET) inhibitor, and a drug-drug conjugate (DDC). Its portfolio of development candidates includes taletrectinib (ROS1), safusidenib (mIDH1), NUV-868 (BET), and NUV-1511 (DDC). Taletrectinib is an oral, potent, CNS-active, selective, ROS1 inhibitor specifically designed for the potential treatment of ROS1-positive non-small cell lung cancer (NSCLC). Safusidenib is an oral, potent, targeted inhibitor of mIDH1 being evaluated in a global Phase II trial in patients with low-grade IDH1-mutant glioma. NUV-868 is a BD2-selective oral small molecule BET inhibitor, that inhibits BRD4. It is conducting Phase I/II study of NUV-1511.

Sector

Biotechnology & Medical Research

Calendar

2024-06-05 - Jefferies Global Healthcare Conference

Related indices

Russell 2000

More about the company

Income Statement Evolution

More financial data

Analysts' Consensus

Sell

Buy

Mean consensus

BUY

Number of Analysts

Last Close Price

2.72 USD

Average target price

6.6 USD

Spread / Average Target

+142.65%

Consensus

EPS Revisions

Estimates Revisions

Quarterly earnings - Rate of surprise

Company calendar

Sector Other Biotechnology & Medical Research

	1st Jan change	Capi.
NUVATION BIO INC.	+73.51%	672M
MODERNA, INC.	+45.57%	56.65B
IQVIA HOLDINGS INC.	-7.23%	39.44B
LONZA GROUP AG	+39.19%	39.03B
CELLTRION, INC.	-6.65%	26.86B
ICON PUBLIC LIMITED COMPANY	+12.34%	26.75B
ALNYLAM PHARMACEUTICALS, INC.	-21.47%	19.03B
BIO-TECHNE CORPORATION	+0.89%	12.28B
UNITED THERAPEUTICS CORPORATION	+23.61%	12.26B
MEDPACE HOLDINGS, INC.	+27.01%	12.04B

Other Biotechnology & Medical Research

Nuvation Bio Inc.

Equities

NUVB

US67080N1019

Biotechnology & Medical Research

Panacea Acquisition Corp. has Changed its Name to Nuvation Bio Inc

Latest news about Nuvation Bio Inc.

Chart Nuvation Bio Inc.

Company Profile

Income Statement Evolution

Analysts' Consensus

EPS Revisions

Quarterly earnings - Rate of surprise

Sector Other Biotechnology & Medical Research